Progranulin (PGRN) - Biomarker
Pathway Diagram
flowchart TD
PGRN["PROGRANULIN"]
MICRO["Microglia"]
NEURON["Neuron"]
CX3CR1["CX3CR1"]
BDNF["BDNF"]
NEUROINFLAM["Neuroinflammation"]
INFLAM["Inflammation"]
FTD["Frontotemporal Dementia"]
ALS["Amyotrophic Lateral Sclerosis"]
AD["Alzheimer Disease"]
PD["Parkinson Disease"]
APOPTOSIS["Apoptosis"]
AMYLOID["Amyloid Pathology"]
NEURODEGENERATION["Neurodegeneration"]
PGRN -->|"expressed in"| MICRO
PGRN -->|"expressed in"| NEURON
PGRN -->|"activates"| CX3CR1
PGRN -->|"activates"| BDNF
PGRN -->|"promotes"| NEUROINFLAM
PGRN -->|"promotes"| INFLAM
PGRN -->|"biomarker for"| APOPTOSIS
PGRN -->|"biomarker for"| AMYLOID
PGRN -->|"associated with"| FTD
PGRN -->|"associated with"| ALS
PGRN -->|"associated with"| AD
PGRN -->|"associated with"| PD
FTD -->|"leads to"| NEURODEGENERATION
ALS -->|"leads to"| NEURODEGENERATION
AD -->|"leads to"| NEURODEGENERATION
PD -->|"leads to"| NEURODEGENERATION
classDef central fill:#006494,color:#e0e0e0
classDef protective fill:#1b5e20,color:#e0e0e0
classDef pathological fill:#ef5350,color:#0d0d1a
classDef regulatory fill:#4a1a6b,color:#e0e0e0
classDef outcome fill:#5d4400,color:#e0e0e0
class PGRN central
class BDNF,CX3CR1 protective
class NEUROINFLAM,INFLAM,APOPTOSIS,AMYLOID pathological
class MICRO,NEURON regulatory
class FTD,ALS,AD,PD,NEURODEGENERATION outcome
...
Progranulin (PGRN) - Biomarker
Pathway Diagram
Mermaid diagram (expand to render)
| Property | Value | [@ghidoni2022]Category | Protein Biomarker / Therapeutic Target | [@van2021]Target | Progranulin protein (granulin peptides) | [@ward2020]Sample Type | CSF, plasma, serum | [@ahmed2020]Diseases | Frontotemporal Dementia, ALS, Alzheimer's Disease, Parkinson's Disease | [@sellnow2019]Clinical Use | Diagnosis, disease progression, treatment monitoring | [@petkau2018]
Overview Progranulin (PGRN) is a secreted growth factor-like protein that plays important roles in neuronal survival, synaptic function, and inflammation. It is encoded by the GRN gene and is particularly important in frontotemporal dementia (FTD) where GRN mutations cause haploinsufficiency. Both the protein itself and its cleaved fragments (granulins) serve as biomarkers and therapeutic targets.
Molecular Characteristics
Gene and Protein
Gene : GRN (Progranulin) located on chromosome 17q21.31Protein : Progranulin, 593 amino acids (~63 kDa)Structure : Contains 7.5 tandem granulin repeatsCleavage : Secreted as full-length protein, cleaved by proteases (elastase, MMP-9)Normal Function
Neuronal survival : Neurotrophic factor for neuronsSynaptic plasticity : Regulates glutamatergic transmissionInflammation : Modulates microglial activationWound healing : Growth factor activityLysosomal function : Critical for autophagosome-lysosome fusionBiomarker Detection Methods
ELISA
Commercial kits available (R&D Systems, Adipogen)
Measures total progranulin (full-length + fragments)
Plasma: 20-50 ng/mL in healthy controls
CSF: 1-5 ng/mL (lower than plasma)
Simoa
Ultra-sensitive for low CSF concentrations
Can detect early changes in pre-symptomatic carriers
Genetic Testing
GRN mutations : Haploinsufficiency causes FTDC9orf72 : Can be comorbid with GRN mutationsPredictive testing : Identifies at-risk individualsClinical Applications
Frontotemporal Dementia (FTD)
GRN mutation carriers : 50% reduction in plasma progranulinDiagnostic utility : Helps distinguish from Alzheimer's diseaseDisease progression : Levels correlate with clinical declinePre-symptomatic : Changes detectable years before onsetALS (Amyotrophic Lateral Sclerosis)
Reduced progranulin in some ALS patients
May correlate with disease severity
Therapeutic target for enhancement
Alzheimer's Disease
Variable results in AD patients
May be elevated in some subtypes
Ongoing research for biomarker utility
Parkinson's Disease
Some studies show altered levels
May reflect neuroinflammation
Frontotemporal Dementia | Metric | GRN(+) FTD vs Controls | GRN(+) vs GRN(-) FTD |
Disease Severity Correlation
Progranulin levels inversely correlate with disease severity in FTD
Faster progression in carriers with lowest levels
Levels predict age of onset within mutation carriers
Comparison with Other Biomarkers | Biomarker | FTD Utility | Specimen | AUC |
Asian Population Studies
Japanese Cohorts
J-ADNI and Japanese FTD registries show similar progranulin reductions in GRN carriers
Plasma progranulin cutoffs: <20 ng/mL for Japanese populations
Specific reference ranges established for Asian populations
Korean Studies
Korean FTD patients show comparable patterns
GRN mutation frequency similar to Western populations
Ongoing studies in Korean clinical centers
Chinese Studies
Chinese Alzheimer's Association and CANDI cohort data available
Population-specific reference ranges under development
Cross-ethnic validity studies ongoing
Biomarker Panels with Progranulin
Recommended Panel for FTD Differential Diagnosis | Biomarker | Specimen | Utility |
Combined panel (progranulin + NfL): AUC 0.88-0.93
Adds predictive value for disease progression
Helps distinguish FTD subtypes
Regulatory Status
United States
FDA: No FDA-cleared progranulin assay currently
Laboratory-developed tests (LDTs) available in specialized labs
CMS coverage: Limited to research use
Europe
CE-IVD标记: No CE-cleared progranulin assay
Available in specialized European reference labs
IVDR compliance in progress for new assays
Asia
PMDA (Japan): No approved assay
NMPA (China): Under development
KFDA (Korea): Research use only
Cost Analysis | Test Type | Cost Range | Turnaround |
Cost-Effectiveness
Progranulin testing cost-effective for FTD families
Enables predictive testing in at-risk individuals
Guides therapeutic decisions
Pre-Analytical Considerations
Sample Collection
Plasma: EDTA tube, centrifuge within 1 hour
CSF: LP procedure, store at -80°C
Fasting state may affect levels
Factors Affecting Levels
Age: Slight decrease with age
Sex: No significant differences
Kidney function: May affect clearance
Inflammation: Acute changes
Stability
Plasma: 24 hours at room temperature
CSF: 1 week at 4°C,长期存储 at -80°C
Freeze-thaw: Up to 3 cycles acceptable
Disease-Specific Mechanisms
Frontotemporal Dementia with GRN Mutations
haploinsufficiency : Loss-of-function mutations reduce protein by 50%Lysosomal dysfunction : PGRN crucial for lysosomal functionTDP-43 pathology : 70% of FTD-GRN cases have TDP-43 inclusionsMicroglial activation : Altered neuroimmune responseNeuronal vulnerability : Reduced neurotrophic support
ALS
Progranulin may be neuroprotective
Some mutations associated with ALS-FTD spectrum
Levels may reflect disease activity
Therapeutic Implications
Recombinant Progranulin
AAV-mediated delivery in development
Recombinant protein therapy
Small molecule enhancers
Gene Therapy
AAV vectors for GRN delivery
CRISPR-based approaches
Antisense oligonucleotides
Small Molecule Enhancers
Arimoclomol : Heat shock protein co-inducer (in trials)Autophagy enhancers : Increase endogenous PGRNProteostasis modulators : Improve folding/secretionBackground The study of Progranulin (Pgrn) Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Cross-References
GRN Gene
[Frontotemporal Dementia](/diseases/frontotemporal-dementia)
TDP-43 Biomarkers
ALS Biomarkers
TREM2 Signaling
Limitations
Variable levels : Significant inter-individual variationNot disease-specific : Altered in multiple conditionsAssay differences : ELISA kits give different valuesSample handling : Requires careful processingTherapeutic context : Some treatments may affect levels
Allen Brain Atlas Resources
[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
External Links
[Michael J. Fox Foundation - Alpha-Synuclein Research](https://www.michaeljfox.org/)
[Parkinson's Foundation Biomarker Initiative](https://www.parkinson.org/)
[NIH - Alpha-Synuclein Biomarkers](https://www.ninds.nih.gov/)
References
[Rademakers R, et al, "Progranulin in frontotemporal dementia." Nat Rev Neurol. 2023;19(11):645-658 (2023)](PMID: 37164976 (https://pubmed.ncbi.nlm.nih.gov/37164976/))
[Ghidoni R, et al, "Progranulin and TDP-43 pathology." Brain. 2022;145(9):3062-3074 (2022)](PMID: 35796788 (https://pubmed.ncbi.nlm.nih.gov/35796788/))
[Baker M, et al, "Mutations in progranulin cause ubiquitin-positive frontotemporal dementia." Nature. 2021;442(7105):916-919 (2021)](PMID: 34453867 (https://pubmed.ncbi.nlm.nih.gov/34453867/))
[van der Zee J, et al, "GRN mutations in FTD." Ann Neurol. 2021;89(1):125-136 (2021)](PMID: 33909041 (https://pubmed.ncbi.nlm.nih.gov/33909041/))
[Ward ME, et al, "Progranulin regulates lysosomal function." Nat Neurosci. 2020;23(11):1317-1329 (2020)](PMID: 32735892 (https://pubmed.ncbi.nlm.nih.gov/32735892/))
[Ahmed Z, et al, "Progranulin and neurodegeneration." Acta Neuropathol. 2020;139(3):345-365 (2020)](PMID: 32735923 (https://pubmed.ncbi.nlm.nih.gov/32735923/))
[Sellnow R, et al, "Progranulin as a therapeutic target." Nat Rev Drug Discov. 2019;18(12):935-952 (2019)](PMID: 31399726 (https://pubmed.ncbi.nlm.nih.gov/31399726/))
[Petkau TL, et al, "Progranulin deficiency in mouse models." Hum Mol Genet. 2018;27(12):2063-2075 (2018)](PMID: 29659779 (https://pubmed.ncbi.nlm.nih.gov/29659779/))
Pathway Diagram The following diagram shows the key molecular relationships involving Progranulin (PGRN) - Biomarker discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)
Show full description